Pharmaceutical Pfizer is commissioned to produce the medicinal product Remdesivir. Gilead’s viral inhibitor was approved earlier this year in the United States and the European Union for the treatment of severely ill patients with Covid-19, the disease caused by the coronavirus. The effectiveness of the drug is questioned by many researchers, but authorities are pushed ‘to do something’. Gilead hopes to increase Remdesivir production with Pfizer’s help. By the end of this year, there should be enough of the drug to treat more than 2 million Covid-19 patients. Gilead previously agreed that almost the entire stock of Remdesivir will be delivered to the United States until September. Pfizer is not the only pharmaceutical to make Gilead Remdesivir. British Hikma Pharmaceuticals has been producing the product since Friday at a factory in Portugal, reported the company. According to Gilead, the pharmaceutical manufacturing network now covers 40 companies in North America, Europe and Asia.
